Buy Dorzox Eye Drop 5ml Online
Dorzolamide Opthalmic as the name suggests is an eye care medication. It reduces the amount of fluid in the eye which lowers pressure inside the eye. High intraocular pressure or IOP (fluid pressure inside the eye) is a major risk factor for glaucoma. Dorzolamide is mainly prescribed for the treatment of some types of glaucoma and other causes of high IOP.
Dorzolamide is sold under various trade names, some of which are Trusopt and Dorzox (produced by Cipla).
How is Dorzox Eye Drops used?
Dorzox Eye Drops is usually applied to the affected eyes 3 times per day or as directed by a doctor. Contact a doctor for the correct dosage and length of treatment as it will depend on the patient’s condition and their response to the medication. To apply the eye drop, tilt the head back and pull on the lower lid of the eye to create a pocket for the medication. Hold the dropper above your eye and release one drop into the eye. Press gently on the inside corner of the eye and close your eye for a minute or two. Repeat the process as required.
Patients using Dorzox Eye Drops may encounter unwanted side effects such as:
- Blurred vision
- Unusual taste in mouth
- Burning or stinging in the eye
Contact a doctor immediately should side effects persist or encounter more severe side effects such as:
- Sensitivity to light
- Itchy eyes
- Redness or swelling eyes
- Dry or watery eyes
- Dark urine
Remove contact lenses prior to applying the medication and wait at least 15 minutes after application to put contact lenses back on.
Immediately proceed to your nearest emergency department if you suffer an allergic reaction. Symptoms usually associated with such a reaction include difficulty breathing or swallowing, chest tightness, swelling, skin rashes, and hives.
Dorzox Eye Drops is not always suitable for all patients. Always consult your health care provider prior to using this medication if you are pregnant, breastfeeding, trying to conceive, using any other medication (prescription or non-prescription), using any herbal products or supplements, or if you have any allergies or other health problems.
The correct dosage and prescription commonly depend on the patient and the condition being treated. Do not adjust your dosage without the approval of your health care provider. This product is only for use as prescribed and instructed.
The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide HCl ophthalmic solution has not been studied in patients with acute angle-closure glaucoma.
Dorzolamide HCl ophthalmic solution has not been studied in patients with severe renal impairment (CrCl < 30 mL/min). Because dorzolamide HCl ophthalmic solution and its metabolite are excreted predominantly by the kidneys, dorzolamide HCl ophthalmic solution is not recommended in such patients.
Therapy with oral carbonic anhydrase inhibitors has been associated with urolithiasis as a result of acid-base disturbances, especially in patients with a prior history of renal calculi. Although no acid-base disturbances have been observed with dorzolamide, urolithiasis has been reported infrequently. Because dorzolamide is a topical carbonic anhydrase inhibitor that is absorbed systemically, patients with a prior history of renal calculi may be at increased risk of urolithiasis while using dorzolamide.
Dorzolamide HCl ophthalmic solution has not been studied in patients with hepatic impairment and should, therefore, be used with caution in such patients.
In clinical studies, local ocular adverse effects, primarily conjunctivitis and lid reactions, were reported with chronic administration of dorzolamide HCl ophthalmic solution. Many of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. If such reactions are observed, dorzolamide HCl ophthalmic solution should be discontinued and the patient evaluated before considering restarting the drug.
There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide HCl ophthalmic solution. The concomitant administration of dorzolamide HCl ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended.
There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
Choroidal detachment concomitant with ocular hypotony has been reported with the administration of aqueous suppressant therapy (e.g. dorzolamide) after filtration procedures.
Corneal oedemas and irreversible corneal decompensations have been reported in patients with pre-existing chronic corneal defects and/or a history of intra-ocular surgery while using dorzolamide HCl ophthalmic solution. There is an increased potential for developing corneal oedema in patients with low endothelial cell counts. Precautions should be used when prescribing dorzolamide HCl ophthalmic solution to this group of patients.
No studies on the effects on the ability to drive and use machines have been performed. Possible side effects such as dizziness and visual disturbances may affect the ability to drive and use machines.
Patients should be advised that dorzolamide HCl ophthalmic solution contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted after 15 minutes following dorzolamide HCl ophthalmic solution administration.